Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634972 · ClinicalTrials.gov registry record · Phase 4
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
A Phase 4 study, sponsored by University of South Alabama.
- Terminated
- Registry status
- Phase 4
- Development phase
- 83
- Enrollment target
NCT00634972: Clinical Trial Phase 4 study, sponsored by University of South Alabama.
NCT00634972 is a Phase 4 study that was terminated before completion, run by University of South Alabama. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634972, a Phase 4 study, was terminated before completion, sponsored by University of South Alabama.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be compared to a placebo (artificial tear). The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to severe ROP (grade II and above)by 50%.
Interventions
- DRUG placebo
- DRUG ACULAR
- DRUG REFRESH TEARS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00634972
The ClinicalTrials.gov registry entry for NCT00634972 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Alabama, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00634972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00634972 about?
NCT00634972 is a clinical study titled "Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity". The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be compared to a placebo (artificial tear). The hypothesis would be that...
What is the current status of trial NCT00634972?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2005-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00634972?
The interventions under investigation include: placebo (DRUG), ACULAR (DRUG), REFRESH TEARS (DRUG).
Who is sponsoring clinical trial NCT00634972?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.